RBC raises Tenet Healthcare price target to $283 from $236

RBC Capital Markets has raised its price target for Tenet Healthcare (NYSE: THC) to $283 from $236, reflecting a more optimistic outlook on the company’s financial performance and operational trajectory. The adjustment follows recent earnings reports that highlighted improved revenue trends and cost management efforts [1]. Analysts at RBC noted that the healthcare provider has demonstrated resilience amid ongoing industry challenges, including inflationary pressures and regulatory changes. The firm’s updated price target suggests a potential upside for investors, based on its assessment of Tenet’s ability to maintain profitability and expand market share in the coming quarters. The move comes as Tenet continues to focus on operational efficiency and strategic investments in key service lines. While the stock has shown volatility in recent months, RBC’s revised target indicates confidence in the company’s long-term positioning within the healthcare sector. Investors are advised to monitor upcoming earnings reports and industry developments for further insights into Tenet’s performance.